Table S5. Clinical outcomes.

Study	Mortality	Stroke	Spinal cord injury	Acute kidney injury	ICU stay [days]
Acute/emergent
Sun	7 [5]	4 [3]	3 [2]	1 [1]	NR
Zhao	1 [4]	0 [0]	0 [0]	NR	NR
Jakob	22 [16]	10 [7]	6 [4]	NR	NR
Shia	3 [4]	0 [0]	0 [0]	4 [6]	NR
Shia	5 [6]	0 [0]	0 [0]	7 [8]	NR
Shib	2 [4]	0 [0]	0 [0]	4 [7]	NR
Zhang	5 [6]	2 [2]	0 [0]	2 [2]	NR
Katayama	7 [6]	4 [3]	2 [2]	4 [3]	NR
Chen	6 [27]	0 [0]	NR	NR	10±11
Chen	3 [27]	1 [9]	NR	NR	12±12
Kobayashi	5 [15]	2 [6]	NR	NR	NR
Aalaei-Andabili	4 [17]	2 [9]	1 [4]	6 [26]	11±6*
Hu	8 [8]	0 [0]	0 [0]	NR	3±2
Shrestha	11 [11]	18 [18]	1 [1]	21 [21]	6±5*
Yamane	2 [8]	1 [4]	0 [0]	NR	NR
Berger	2 [6]	4 [13]	0 [0]	NR	NR
Goebel	11 [15]	2 [3]	3 [4]	18 [25]	6±5*
Lopez Almodovar	2 [17]	1 [8]	0 [0]	NR	NR
Ma	19 [14]	7 [5]	0 [0]	20 [15]	8±4
Roselli	3 [4]	3 [4]	3 [4]	2 [3]	NR
Kremer	5 [15]	3 [9]	3 [9]	23 [68]	9±9
Lin	3 [6]	1 [2]	0 [0]	5 [9]	4±4
Qian	25 [11]	2 [1]	5 [2]	35 [16]	3±3
Tochii	0 [0]	4 [18]	0 [0]	2 [9]	11±12
Yamamoto	3 [3]	4 [4]	0 [0]	6 [6]	NR
Subtotal	9.4 [7.4–11.9]	4.7 [3.1–6.9]	2.6 [1.9–3.7]	10.5 [6.5–16.4]	7 [5–8]
Chronic/elective
Flores	3 [12]	4 [16]	6 [24]	NR	NR
Uchida	1 [2]	2 [3]	2 [3]	1 [2]	NR
Sun	2 [1]	3 [2]	4 [3]	2 [1]	NR
Jakob	20 [14]	7 [5]	13 [9]	NR	NR
Nakamura	NR	NR	2 [4]	NR	NR
Aalaei-Andabili	4 [16]	1 [4]	1 [4]	6 [24]	13±9*
Shrestha	9 [11]	11 [13]	3 [4]	16 [20]	5±5*
Shrestha	3 [4]	8 [12]	0 [0]	15 [22]	7±8*
Berger	2 [6]	2 [6]	0 [0]	NR	NR
Zhong	2 [6]	0 [0]	0 [0]	NR	NR
Kremer	5 [15]	4 [12]	2 [6]	16 [47]	9±9
Subtotal	8.3 [5.2–12.8]	7.2 [4.5–11.3]	5 [2.8–8.8]	14.5 [6.3–29.6]	8 [5–11]
Mixed
Leontyev	4 [8]	6 [12]	10 [20]	13 [25]	NR
Weiss	2 [7]	3 [11]	2 [7]	8 [30]	4±11*
Mkalaluh	5 [20]	6 [24]	1 [4]	6 [24]	11±11*
Tsagakis	32 [11]	16 [6]	14 [5]	91 [32]	NR
Alhussaini	9 [19]	3 [6]	2 [4]	NR	NR
Chu	2 [5]	3 [8]	2 [5]	1 [3]	2±2*
Dinato	16 [20]	4 [5]	2 [3]	38 [48]	NR
Kozlov	0 [0]	1 [7]	0 [0]	NR	NR
Kozlov	0 [0]	0 [0]	0 [0]	NR	NR
Leone	48 [17]	25 [9]	17 [6]	55 [20]	1±3*
Zhang	87 [11]	36 [4]	56 [7]	263 [32]	3±3
Subtotal	13.1 [10.2–16.6]	7.7 [5.4–10.7]	6.5 [4.7–9]	28.6 [22.3–35.8]	3 [1–4]
Overall	10.2 [8.7–12]	6.2 [5–7.8]	4.1 [3.2–5.4]	15.5 [11.9–20.1]	6 [5–7]

Data is presented as number of patients [%] or mean ± standard deviation. Aggregated subtotal and overall values are presented with 95% confidence intervals, using random-effects meta-analysis of proportions or means. *, mean and standard deviation recalculated using methods of Wan et al. ^a, DOI: 10.1016/j.jtcvs.2013.10.058; ^b, DOI: 10.1016/j.jtcvs.2014.02.077.